Le Lézard
Classified in: Health
Subjects: RCL, PSF, CFG

Public Health Notice: Outbreak of Salmonella infections linked to Malichita brand cantaloupes


OTTAWA, ON, Nov. 22, 2023 /CNW/ - Update

Why you should take note

The Public Health Agency of Canada (PHAC) is collaborating with federal and provincial public health partners, the United States Centers for Disease Control and Prevention (U.S. CDC), and the U.S. Food and Drug Administration (FDA) to investigate an outbreak of Salmonella infections in five provinces: British Columbia, Ontario, Quebec, Prince Edward Island and Newfoundland and Labrador.

Based on the investigation findings to date, consumption of Malichita brand cantaloupe has been identified as the likely source of the outbreak. Some of the individuals who became sick reported having eaten cantaloupe before their illnesses occurred.

The CFIA issued food recall warnings on November 1 and November 14 for Malichita brand cantaloupes sold between October 11 and November 14, 2023. The recalled product was distributed in Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Prince Edward Island, Quebec, and possibly other provinces and territories. Additional secondary recalls have been issued for products that were made using the recalled Malichita brand cantaloupe and for produce items that were processed alongside Malichita brand cantaloupes. This includes other fruit like honeydew, pineapple, watermelon and various fruit trays. For more information on the recalled products, please consult CFIA's recall notice.

The CFIA is continuing its food safety investigation, which may lead to the recall of other products. If other products are recalled, the CFIA will notify the public through additional food recall warnings.

To prevent illness, do not eat, serve, use, sell, or distribute Malichita brand cantaloupe, any products made with Malichita brand cantaloupe, or any recalled produce. If you are unable to verify the brand of cantaloupe, or if your produce is part of the CFIA recalls, it is recommended to throw it out. This advice applies to individuals, as well as retailers, distributors, manufacturers, food service establishments such as hotels, restaurants, cafeterias, and facilities such as hospitals, long-term care homes and daycares, across Canada.

This public health notice will be updated as the investigation evolves.

Symptoms

Symptoms typically start 6 to 72 hours after exposure to Salmonella bacteria, and usually last for 4-7 days.

Symptoms may include:

People who are infected with Salmonella bacteria can spread Salmonella to other people several days to several weeks after they have become infected, even if they don't have symptoms. Salmonella can spread by person to person contact and contaminated surfaces. Most people who become ill from a Salmonella infection will recover fully after a few days without treatment, but it can also cause severe illness and hospitalization.

Anyone can become sick with a Salmonella infection. If you think you're experiencing symptoms, contact your health care provider.

Those at higher risk for serious illness include:

What you should do to protect your health

The following advice applies to individuals, as well as retailers, distributors, manufacturers, food service establishments such as hotels, restaurants, cafeterias, and facilities such as hospitals, long-term care homes and daycares, across Canada:

Additional information

SOURCE Public Health Agency of Canada


These press releases may also interest you

at 00:16
WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043. This landmark achievement marks the world's first approval of an EB virus-related mRNA...

at 00:00
SN Bioscience Co. Ltd. (CEO Park Young-hwan) announced on May 7 that the FDA has granted Fast Track Designation for small cell lung cancer (SCLC) for SNB-101 (API: SN-38), a new drug for polymer nanoparticle anticancer under clinical trial. SNB-101...

9 mai 2024
TCI Group is proud to be participating in Phase 1 of the Alliance for Water Stewardship (AWS) Impact Accelerator. Together we are working in Shanghai Jinshan with AWS Members and five other facilities to expand our knowledge, skills and networks to...

9 mai 2024
A research team led by The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been awarded approximately $11 million over five years by the National...

9 mai 2024
Celltrion USA announced today that adalimumab-aaty, the company's high-concentration (100 mg/mL) and citrate-free formulation biosimilar to HUMIRA ® (adalimumab), is now available at a low wholesale acquisition cost (WAC). Adalimumab-aaty will be...

9 mai 2024
Rakuten Medical, Inc., a global...



News published on and distributed by: